The use of aromatase inhibitors in in vitro fertilization.
The use of aromatase inhibitors (AIs) in IVF patients remains controversial. AIs can be considered for ovulation induction for IVF in women who are normal and poor responders, are at risk of ovarian hyperstimulation syndrome or thrombosis, who have endometriosis, and/or are undergoing fertility preservation procedures as a result of estrogen-dependent cancers, primarily breast and endometrial cancers. Although the biologic plausibility of the capacity of AIs in IVF patients is promising, results should be interpreted with caution, because the efficacy of AIs needs to be proven in randomized trials.
IVI-Madrid, Rey Juan Carlos University, Madrid, Spain. juan.garcia.velasco@ivi.es
Juan A
JA
Garcia-Velasco
D047072:Aromatase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D005307:Fertilization in Vitro / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D007247:Infertility, Female / Q000628:therapy*; D010062:Ovulation Induction / Q000009:adverse effects / Q000379:methods*
D047072:Aromatase Inhibitors